The enhancement of anti-PD-L1 antibody efficacy by MAC, CD8+ T cell reinvigoration, and Treg cell reduction were confirmed in TNBC, colon, and lung cancer mouse xenograft models, indicating that MAC could be effective in various EDNRA-expressing cancer types. Here, CD8A is linked to lung carcinoma.